ALK and lung carcinoma: Lung cancer ranks as one of the most prevalent and lethal malignancies worldwide.[1] While fewer than 5% of lung cancer cases metastasize to uncommon sites, ovarian metastasis occurs in merely 0.07% of cases.[2] The EML4-ALK-fusion is detected in only 3% to 5% of non-small cell lung cancer (NSCLC) patients.[3] Consequently, EML4-ALK-fusion-positive lung adenocarcinoma with ovarian metastasis represents an exceptionally rare clinical scenario.